ABSTRACT
Introduction Chronic non-malignant pain is a disabling condition that results in a reduction in function and quality of life when inadequately managed. Sub-lingual ketamine has been shown to be efficacious for use in chronic pain. Despite its use for decades in chronic non-malignant pain, there is no published long-term data on safety, side effects or adverse drug reactions. The aim of this case-series is to provide the initial evidence for safety and efficacy in this patient group.
Methods We present a retrospective review of twenty-nine patients (n=29) from a metropolitan tertiary pain service who have been receiving sub-lingual ketamine troches / lozenges between the period of 2012-2019. Patients were identified from the outpatient pain clinic, who had been admitted for inpatient subcutaneous ketamine infusions as part of opiate detoxification or management of central sensitisation due to a chronic neuropathic pain syndrome. An initial review was performed to check the patient started taking the ketamine troches. Each of these medical records was reviewed manually to extract information to a datasheet.
Results There was a wide range of dosages used from 25-600mg in divided doses. The duration of treatment ranged from 2-89 months. There was no association with either the dosage or duration of treatment and frequency of side effects. There was an overall reduction in the use of opioids, gabapentinoids or benzodiazepines in 59% of patients with 39% having a complete cessation of an analgesic agent. Side effects were reported in 24%, but only 7% discontinued the treatment due to the side effect (drowsiness). There were no reports of renal impairment, cystitis, or hepatotoxicity.
Discussion This retrospective case-series has demonstrated that sub-lingual ketamine is a safe and effective analgesic agent to use in chronic non-malignant pain management. It is indicated in a variety of chronic pain conditions and has an excellent safety profile, with no association between the frequency in side effects and duration of therapy or total daily dosages. The study has also shown that the “safe” dose may be higher than the previous consensus.
Contribution Statement A.A and S.G. recruited the patients. A.A. & B.M. created the parameters for the data collection sheet. B.M Collected most of the data from the medical records, entered it into a datasheet, wrote the manuscript, ran the statistics, performed the data analysis, and generated the figures and tables. A.A. Edited the manuscript. S.G. and A.A were the research supervisors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None declared
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Sydney Local Health District Human Ethics Committee approved the study. It was deemed low-negligible risk.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding sources: None declared
Device status: None declared
Ethics: The Sydney Local Health District Human Ethics Committee approved the study. It was deemed low-negligible risk.
Declaration of interest: The authors have no other relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.
MeSH Terms: (((“ketamine”[MeSH Terms] OR “ketamine/adverse effects”[MeSH Terms] OR “ketamine/history”[MeSH Terms] OR “ketamine/metabolism”[MeSH Terms] OR “ketamine/pharmacokinetics”[MeSH Terms] OR “ketamine/pharmacology”[MeSH Terms] OR “ketamine/physiology”[MeSH Terms] OR “ketamine/poisoning”[MeSH Terms] OR “ketamine/therapeutic use”[MeSH Terms] OR “ketamine/toxicity”[MeSH Terms]))) AND ((“chronic pain”[MeSH Terms] OR “chronic pain/classification”[MeSH Terms] OR “chronic pain/drug therapy”[MeSH Terms] OR “chronic pain/epidemiology”[MeSH Terms] OR “chronic pain/etiology”[MeSH Terms] OR “chronic pain/immunology”[MeSH Terms] OR “chronic pain/therapy”[MeSH Terms])))
Data Availability
Data was collected from Pain Clinic Letters and Electronic Medical Records